2026-07-30 09:03:35 / 路透社
堪萨斯州埃尔斯沃思市63岁的越南战争老兵拉里·爱德华兹（Larry Edwards）的私人车牌印有“PTSD”字样，以表明自己仍受服役期间患上的创伤后应激障碍困扰。2013年5月25日，他与数十万摩托车骑手一同抵达弗吉尼亚州费尔法克斯，参加阵亡将士纪念日周末举办的第26届…… 获取授权，打开新标签页 查看更多
- 内容摘要
- 常规治疗无效的退伍军人创伤后应激障碍患者，在一项小型早期试验中通过致幻剂获得症状缓解
- 12名前士兵中多数在接受治疗后实现症状缓解
- 研究人员将规划更大规模试验，并持续追踪当前受试者
7月30日（路透社）——研究人员表示，在美国一项小型前瞻性试点研究中，常规治疗无效的创伤后应激障碍退伍军人，在接受致幻剂裸盖菇素治疗后实现了症状缓解。
在美国，裸盖菇素与几乎所有其他致幻药物均被列为与海洛因或摇头丸同类的管制物质，被认定无医疗用途且滥用风险极高。
订阅路透社健康周刊，随时了解最新医学突破与医疗健康趋势。 点击此处注册。
今年4月，唐纳德·特朗普总统签署行政令，要求卫生监管机构加快致幻剂疗法的审批流程，并增加联邦 funding 用于相关研究。
这项早期研究是首次正式针对创伤后应激障碍退伍军人测试该疗法，俄亥俄州立大学社会工作学院的研究负责人艾伦·戴维斯（Alan Davis）表示，该研究进一步证实了裸盖菇素——迷幻蘑菇中的活性成分——具有潜在益处。
该试验旨在测试疗法安全性，无法证明裸盖菇素对创伤后应激障碍是有效的治疗手段，但确实表明在更大规模患者群体中开展进一步测试具有价值。
发表在《通讯医学》期刊上的报告显示，试验中的12名退伍军人中有9人在治疗一个月后不再符合创伤后应激障碍的诊断标准。
“对于这类难治性重症创伤后应激障碍患者群体而言，这些结果令人瞩目，”同样来自俄亥俄州立大学的研究合著者斯泰西·阿姆斯特朗（Stacey Armstrong）在一份声明中表示。
这场为期11周的试验包含8小时心理治疗，随后间隔2至3周给予两剂合成裸盖菇素。药物治疗结束后，患者还需接受6至8小时的整合心理治疗。
最常见的副作用是服用裸盖菇素后出现轻度头痛。
“（患者）能够回头直面曾经历的艰难事件，并找到全新的理解方式与生活前进方向，这着实令人振奋，”戴维斯在声明中说道。
在一个月后未实现症状缓解的3名退伍军人中，有2人创伤后应激障碍症状出现小幅改善，仅剩1人症状几乎无减轻。
在澳大利亚，裸盖菇素已被批准用于治疗难治性抑郁症。瑞士也允许有限使用裸盖菇素心理疗法。
参与本次创伤后应激障碍研究的团队表示，他们希望获得资金支持，开展更大规模的随机对照临床试验。
与此同时，他们将持续对当前试验受试者进行长达6个月的疗效评估，同时观察相关生物学变化以及该疗法对睡眠障碍、物质使用障碍等其他创伤后应激障碍相关问题的影响。
南希·拉皮德（Nancy Lapid）报道；林肯·费斯特（Lincoln Feast）编辑
我们的报道准则：遵循路透社汤森路透信托原则，打开新标签页
南希在路透社担任健康新闻记者与编辑已有十余年，报道过诸多重要医学研究进展。她也是每周两期的《路透社健康周刊》专栏作者。
Veterans’ PTSD resolves with psychedelic therapy in small US study
2026-07-30 09:03:35 / Reuters
Vietnam veteran Larry Edwards ,63, of Ellsworth, KS, sports a personal license plate “PTSD” for the Post Traumatic Stress Syndrome he still suffers for his service in Vietnam, as he arrives in Fairfax, Virginia May 25, 2013, along with hundreds of thousands of motorcycle riders gathering on Memorial Day weekend for the 26th… Purchase Licensing Rights, opens new tabRead more
- Summary
- Military veterans with hard-to-treat PTSD got relief from a psychedelic drug in a small early-stage trial
- Most of the 12 former soldiers went into remission after the treatment
- Researchers will plan larger trials and continue to track the current subjects
July 30 (Reuters) – Military veterans with post-traumatic stress disorder who got no relief from conventional treatments went into remission following treatment with the psychedelic drug psilocybin in a small U.S. pilot study, researchers say.
In the United States, psilocybin and almost all other psychedelic drugs are controlled substances in the same class as heroin or ecstasy, meaning they are deemed to have no medical use and high risk for abuse.
Keep up with the latest medical breakthroughs and healthcare trends with the Reuters Health Rounds newsletter. Sign up here.
In April, President Donald Trump signed an executive order directing health regulators to speed reviews of psychedelic treatments and increase federal funding for research into their use.
The current early-stage study – the first to formally test the treatment in veterans with PTSD – adds to earlier evidence suggesting a benefit from psilocybin, the active ingredient in magic mushrooms, said study leader Alan Davis of The Ohio State University College of Social Work.
It was designed to test safety and cannot prove that psilocybin is an effective treatment for PTSD, but does signal the value of further testing in larger groups of patients.
Nine of the 12 veterans in the trial no longer met the criteria for PTSD a month after the treatment, according to a report in Communications Medicine.
“For a population with severe treatment-resistant PTSD, these results are striking,” study coauthor Stacey Armstrong, also of Ohio State University, said in a statement.
The 11-week trial period combined eight hours of psychotherapy followed by two doses of synthetic psilocybin given two to three weeks apart. Six to eight more hours of integrative therapy followed the drug treatment.
The most common side effect was a mild headache after taking psilocybin.
“The ability for (patients) to go back and to revisit really difficult events that happened to them and to find a new way of understanding them and a new way of moving forward in their life has really been exciting,” Davis said in a statement.
Two of the three veterans who were not in remission at one month showed small decreases in PTSD symptoms, while the third person only had negligible decreases in symptoms.
In Australia, psilocybin is authorized for treatment-resistant depression. Switzerland also allows limited use of psilocybin psychotherapy.
The PTSD researchers say they hope to secure funding to follow up with a larger randomized, controlled clinical trial.
In the meantime, they will continue to assess the treatment’s effectiveness up to six months after the current trial, as well as biological changes and effects on other PTSD-related problems like sleep disorders and substance use, they said.
Reporting by Nancy Lapid; editing by Lincoln Feast.
Our Standards: The Thomson Reuters Trust Principles., opens new tab
Nancy has been a health news reporter and editor at Reuters for more than a decade, covering important medical research advances. She is the author of our twice-a-week Reuters Health Rounds newsletter.
发表回复